THOUSAND OAKS, Calif.,
March 30, 2015 /PRNewswire/
-- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key
Debates in Biosimilars conference at 9:05
a.m. ET on Thursday, April 2,
2015, at the Goldman Sachs Conference Center in New York City. Scott
Foraker, vice president and general manager of biosimilars
at Amgen, will present at the conference. Live audio of the
presentation can be accessed from the Events Calendar on Amgen's
website, www.amgen.com, under Investors. A replay of the webcast
will also be available on Amgen's website for 90 days following the
event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Cuyler Mayer, 805-447-6332
(media)
Arvind Sood, 805-447-1060
(investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-goldman-sachs-key-debates-in-biosimilars-conference-300057904.html
SOURCE Amgen